VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
SMMTSummit Therapeutics Inc.
$13.75$10.7B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSMMTRevenue History

SMMT logoSummit Therapeutics Inc. (SMMT) Revenue History

Annual and quarterly revenue from 2003 to present

TTM Revenue$0
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$57.1M (2018)
Best Quarter$49.9M (Q2 2018)

SMMT Revenue Over Time (2003–2025)

SMMT Revenue Growth History

13 of 20 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2003—
2004+11564.5%
2005+345.5%
2006+113.9%
2007+197.1%
2008-95.6%
2009+13.2%
2010+299.7%
2011-7.5%
2012+69.8%
2013-2.7%
2014+2.4%
2015-32.2%
2016+85.5%
2017+496.3%
2018+302.9%
2019-98.9%
2020+2.8%
2021+112.7%
2022-56.4%
2023-100.0%
2024—
2025—
FY2003 revenue growth
N/A
FY2004 revenue growth
+11564.5%
FY2005 revenue growth
+345.5%
FY2006 revenue growth
+113.9%
FY2007 revenue growth
+197.1%
FY2008 revenue growth
-95.6%
FY2009 revenue growth
+13.2%
FY2010 revenue growth
+299.7%
FY2011 revenue growth
-7.5%
FY2012 revenue growth
+69.8%
FY2013 revenue growth
-2.7%
FY2014 revenue growth
+2.4%
FY2015 revenue growth
-32.2%
FY2016 revenue growth
+85.5%
FY2017 revenue growth
+496.3%
FY2018 revenue growth
+302.9%
FY2019 revenue growth
-98.9%
FY2020 revenue growth
+2.8%
FY2021 revenue growth
+112.7%
FY2022 revenue growth
-56.4%
FY2023 revenue growth
-100.0%
FY2024 revenue growth
N/A
FY2025 revenue growth
N/A
DeclineStrong growth
Best: +11564.5% (FY2004)Worst: -100.0% (FY2023)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0—
Q3 2024$0—
Q2 2024$0—
Seasonal Revenue Pattern (fiscal quarters)
Q1
28%
Q2
26%
Q3
25%
Q4
21%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2022)

SMMT's revenue distribution by segment and geography for fiscal year 2022

By Product/Segment

License and Service100.0%

By Geography

Latin America100.0%

SMMT Revenue Analysis (2003–2025)

Current Revenue & Growth

As of June 21, 2026, Summit Therapeutics Inc. (SMMT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

SMMT's historical revenue data shows various trends over time. Summit Therapeutics Inc.'s highest annual revenue of $57.1 million was recorded in 2018.

Revenue by Segment

SMMT's revenue is primarily driven by License and Service (100%). With over half of revenue concentrated in License and Service, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including KYMR (-12.6% YoY), TNGX (+39.0% YoY), and KRYS (+25.1% YoY). Compare SMMT vs KYMR →

SMMT Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
SMMT logoSMMTCurrent$0---
KYMR logoKYMR$39M-12.6%+2.9%-891.3%
TNGX logoTNGX$62M+39.0%+52.1%-178.4%
KRYS logoKRYS$389M+25.1%-41.5%
Best in groupLowest in group

SMMT Historical Revenue Data (2003–2025)

1–15 of 23 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-1,094,374,000-
2024$0-$0-$-180,513,000-
2023$0-100.0%$0-$-478,227,000-
2022$583K-56.4%$583K100.0%$-59,633,462-10225.4%
2021$1.3M+112.7%$1.3M100.0%$-63,731,961-4764.3%
2020$629K+2.8%$629K100.0%$-38,897,381-6185.2%
2019$612K-98.9%$612K100.0%$-22,624,463-3697.6%
2018$57.1M+302.9%$56.4M98.8%$5.4M9.4%
2017$14.2M+496.3%$14.2M100.0%$-25,829,000-182.3%
2016$2.4M+85.5%$2.4M100.0%$-24,853,000-1046.0%
2015$1.3M-32.2%$1.3M100.0%$-20,346,000-1588.3%
2014$1.9M+2.4%$1.9M100.0%$-12,233,000-647.9%
2013$1.8M-2.7%$1.8M100.0%$-6,709,000-363.8%
2012$1.9M+69.8%$1.9M100.0%$-4,577,000-241.5%
2011$1.1M-7.5%$1.1M100.0%$-1,898,615-170.1%
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into SMMT consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

23+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SMMT — Frequently Asked Questions

Quick answers to the most common questions about buying SMMT stock.

Is SMMT's revenue growth accelerating or slowing?

SMMT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is SMMT's revenue history from 2003 to 2026?

Summit Therapeutics Inc. (SMMT) revenue history spans 2003 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is SMMT's long-term revenue growth rate (CAGR)?

Summit Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SMMT.

Why does SMMT's quarterly revenue fluctuate?

SMMT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Summit Therapeutics Inc.'s revenue data from 2003 to 2026 shows full historical quarterly detail on this page.

How is SMMT's revenue distributed by segment?

SMMT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does SMMT's revenue compare to industry peers?

Summit Therapeutics Inc. (SMMT) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.